Changes in systemic medication in children and adolescents with juvenile idiopathic arthritis: why, when and which patterns
Clicks: 1
ID: 317081
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #80 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVE: To investigate why, when and in which patterns decisions about changes in systemic medications were made in a cohort of juvenile idiopathic arthritis (JIA) patients. METHODS: JIA patients starting first line systemic therapy were prospectively followed in a Dutch tertiary pediatric rheumatology center. Treatment lines were constructed for the included systemic therapies (systemic corticosteroids, conventional and biological disease modifying antirheumatic drugs (cDMARDs and bDMARDs)). Each change in systemic medication and its reason was registered. Main outcomes were frequencies and timing of change reasons, across treatment lines. A Sankey diagram was used to visualize flows between change reasons over treatment lines, cumulative incidences Fine-Gray models to illustrate the frequencies of the change reasons over time. RESULTS: 551 patients were included of which 67.9% were female and oligoarticular JIA was the most common JIA diagnosis (41.9%). 1422 different systemic drug treatment lines were observed, with a median number of 2 (IQR 1-3) treatment lines per patient. Methotrexate was predominantly used as first treatment line (89.1%), while bDMARDs were mostly used as next treatment line (53.3%). JIA medication was mostly changed because of inefficacy (42.9%) in the first treatment line vs remission in the second treatment line (46.2%). CONCLUSION: JIA medication is mostly changed because of inefficacy in the first treatment line (predominantly methotrexate) vs remission in the second treatment line (roughly half on bDMARDs). This indicates that bDMARDs may be a more effective treatment than methotrexate in part of the JIA population, advocating reconsideration of current JIA treatment guidelines.
| Reference Key |
openalex_W7164332675
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Merel de Boer, Sytze de Roock, Toine C. G. Egberts, Arief Lalmohamed, Joost F. Swart |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag296
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.